RESULTS
The aim of this study was to evaluate the Budget Impact (BI) of treatment of Crohn's disease with adalimumab (ADA) from the perspective of the Brazilian Private Health Care System (BPHCS) over a 5 year time period.
10,035 patients were eligible for treatment with either IFX or ADA over the five years of analysis. In the base case scenario, the Budget Impact simulation presented a decrease of total cost by R$1,942,434.38 in the first year and reached a decrease of R$9,089,493.93 in the fifth year. The cumulative economic savings for the five years in the simulation with ADA introduction was R$26,879,457.87.
The utilization of ADA may generate economic savings for the Brazilian Private Health Care System that may allow more eligible patients with Crohn's disease to be treated with ADA.
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METHODS
An epidemiological model based on the Private Health Care System population, DataSUS database and published literature was developed to estimate eligible patients in the next five years in Brazil - Figure 1 . The BI was simulated comparing the current scenario (patients treated with intravenous infliximab [IFX] ) with a new scenario (the introduction of ADA for Crohn's disease treatment), BPHCS perspective. The market-share for ADA starts at 20% during the first year and rises to 80% (20, 40, 50, 60 and 80%) - Figure 2 . Dose per application, number of vial/syringe, cost of application and median of weight were based on scientific literature. The drug prices were based on Factory Prices plus 18% taxes from CMED and the treatment cost - Table 2 and Table 3 
